Rapport Therapeutics (RAPP)
Develops RAP-targeted neuromedicines, with RAP-219 advancing across seizure and bipolar mania programs.
$48.69
At close+0.13 (+0.27%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions166 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 107.20% | 51.43M shares | |
| Insiders8 holders · as of Aug 26, 2026 | 3.72% | 1.79M shares | |
| Strategic holders1 holder · as of May 28, 2026 | 13.09% | 6.28M shares | |
| Adds to | 124.01% |
47.98M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 124.01%; nothing is left for Other.
Institutions13F, as of Jun 30, 2026
166 holders · 51.43M shares · 32 new positions · 89 increased · 45 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 7.17M | 14.95% | +4.0K | Aug 13, 2026 |
| TRV GP V, LLC | 6.28M | 13.09% | −854.7K | Aug 10, 2026 |
| Arch Venture Management, LLC | 3.73M | 7.77% | 0 | Aug 14, 2026 |
| Capital International Investors | 2.92M | 6.09% | −176.0K | Aug 12, 2026 |
| Goldman Sachs Group Inc | 2.91M | 6.07% | −31.8K | Aug 14, 2026 |
| BlackRock, Inc. | 2.70M | 5.63% | +193.8K | Aug 7, 2026 |
| Cormorant Asset Management, LP | 2.66M | 5.54% | −300.0K | Aug 14, 2026 |
| Sofinnova Investments, Inc. | 1.90M | 3.97% | 0 | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 19.50% | 7.14M | 13G | Feb 13, 2025 ↗ |
| ARCH Venture Fund XII, L.P. | 10.20% | 3.73M | 13G | Nov 14, 2024 ↗ |
| Capital International Investors | 7.10% | 13G | Nov 13, 2024 ↗ | |
| Cormorant Asset Management, LP | 6.19% | 2.96M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.03% | 2.40M | 13G | Jan 21, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 25, 2026 | Abraham Ceesaydirector, officer: Chief Executive Officer | Sale | 18,921 | $49.57 | 467,187 |
| Aug 25, 2026 | Krishnaswamy Yeleswaramofficer: Chief Development Officer | Sale · 2 lots | 37,000 | $50.64 | 195,862 |
| Aug 24, 2026 | Krishnaswamy Yeleswaramofficer: Chief Development Officer | Sale | 13,160 | $50.00 | 232,862 |
| Aug 19, 2026 | Krishnaswamy Yeleswaramofficer: Chief Development Officer | Sale | 404 | $49.90 | 246,022 |
| Aug 11, 2026 | Abraham Ceesaydirector, officer: Chief Executive Officer | Sale · 3 lots | 28,958 | $48.01 | 486,108 |
| Aug 10, 2026 | Abraham Ceesaydirector, officer: Chief Executive Officer | Sale · 2 lots | 22,541 | $46.26 | 515,066 |
| Jul 27, 2026 | Abraham Ceesaydirector, officer: Chief Executive Officer | Sale · 2 lots | 2,210 | $42.11 | 537,607 |
| Jul 14, 2026 | Abraham Ceesaydirector, officer: Chief Executive Officer | Sale · 2 lots | 8,210 | $40.00 | 539,817 |
| Jun 29, 2026 | Abraham Ceesaydirector, officer: Chief Executive Officer | Sale · 2 lots | 8,220 | $39.83 | 548,027 |
| Jun 30, 2026 | Cheryl Gaultofficer: Chief Operating Officer | Sale · 4 lots | 10,000 | $41.58 | 149,914 |
CongressHouse and Senate disclosures
Not reported.